Oncorena has announced the initiation of the Phase I-II clinical trial of orellanine in patients with advanced kidney cancer on dialysis.
The drug candidate orellanine is being developed for organ-specific chemotherapy with curative potential for patients with advanced kidney cancer undergoing dialysis due to kidney failure. Preclinical evidence shows that orellanine specifically exerts powerful anti-tumor effects on metastatic kidney cancer in different preclinical models.
About the Phase I-II study
The Phase I-II clinical study will include up to 40 patients and may include patients from other European countries. The clinical trial is conducted in collaboration with the Centre for Clinical Cancer Studies, Karolinska University Hospital in Stockholm, Sweden. Since the patients are dialysis-dependent, hemo-dialysis is provided in collaboration with a team at the dialysis unit at the Karolinska Hospital. The study is coordinated together with a clinical research organization specialist in oncology clinical trials.
“There is a great medical need for improved treatment options in patients with advanced kidney cancer undergoing dialysis. We are looking forward to the important clinical development phase in this therapy area. It is our hope that the results from our clinical study will be of great benefit to patients in the future,” says Lars Grundemar, Chief Executive Officer of Oncorena.
Photo of Lars Grundemar: Oncorena